Turning 60 does not make every menopause treatment decision the same. Starting systemic hormone therapy for the first time later in life is a different question from continuing an established treatment that is helping.
Age, time since menopause, symptoms and medical history all shape the discussion. A website’s “over 50” recommendation cannot replace an individualized assessment, and low-dose local vaginal treatment should be considered separately from systemic therapy.
Why timing changes the balance
The Menopause Society describes a generally more favorable benefit-risk balance for appropriate candidates younger than 60 or within 10 years of menopause onset. Starting later can carry greater absolute risks as underlying cardiovascular and other health risks increase. Those timeframes guide discussion; they are not a self-screening tool.
Explain when your last natural period occurred, whether menopause followed surgery and whether you have used hormones before. A clinician needs that history to distinguish a new start from a restart or continuation. If timing is uncertain, say so rather than filling in an approximate date as a fact.
Define the problem you want treated
Persistent hot flashes may deserve a different approach from vaginal dryness, sleep apnea, depression or medication-related sweating. Ask whether the symptoms fit menopause or need another evaluation. New symptoms later in life should not automatically be attributed to low hormones.
Local vaginal treatment may be a more focused option when symptoms are limited to those tissues. Our local-estrogen guide explains why the route and dose can change the conversation.
Review the full medical picture
Bring a history of blood clots, stroke, heart disease, liver disease, cancers and unexplained bleeding. Include blood-pressure information, smoking history and all medicines or supplements. The clinician may need records or an in-person assessment before deciding on treatment.
A patch does not erase those considerations. Transdermal estrogen may have a different clot-risk profile from oral estrogen, but choosing a route is part of the assessment, not a shortcut around it. Never start a friend’s leftover prescription to see whether it helps.
Continuing treatment is not an automatic stop-or-go rule
There is no single stopping date that works for everyone. The decision to continue should revisit benefits, risks, dose, route and alternatives over time. A person with ongoing troublesome symptoms may reach a different decision from someone whose symptoms have settled.
If you want to stop, discuss the plan and what to do if symptoms return. Do not treat a website’s age cutoff or a renewal reminder as a substitute for that review. The clinician can also explain whether nonhormonal options fit your situation.
Choose a service that can handle the complexity
Ask an online clinic whether it treats people your age and with your history, how it coordinates local care and when it refers out. Confirm Medicare-related policies before booking. Our Midi review explains why general insurance acceptance is not the same as Medicare participation.
The over-50 shortlist compares care features and clearly labels promotional ordering. Use it to identify questions about access, not to choose a hormone on the basis of a ranking.
FOLLOW THE EVIDENCE
Sources & further reading
Provider pages support service and price descriptions. Medical guidance supports treatment explanations. Neither is a first-hand review of patient outcomes. Checked September 20, 2026.